New hope to fight bladder cancer and keep your bladder
NCT ID NCT02621151
Summary
This study is testing whether adding an immunotherapy drug (pembrolizumab) to a standard combination of chemotherapy (gemcitabine) and radiation is a safe and effective way to treat muscle-invasive bladder cancer. The goal is to control the cancer and avoid surgically removing the bladder (cystectomy) in patients who are not candidates for or refuse that major surgery. The trial will enroll about 60 participants to see if this approach helps keep patients cancer-free with their bladder intact for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE UROTHELIAL CANCER OF THE BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
NYU Perlmutter Cancer Center
New York, New York, 10016, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599-7305, United States
Conditions
Explore the condition pages connected to this study.